Company Name, Ticker, Industry, else..

Ambrx Biopharma Inc (NASDAQ: AMAM)

Sector • Healthcare Industry • Biotechnology & Pharmaceuticals

Industry • Biotechnology & Pharmaceuticals

Sector • Healthcare

Ambrx Biopharma Inc 's

Name: Ambrx Biopharma Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AMAM Sales vs. its Competitors Q3 2023

Comparing the current results to its competitors, Ambrx Biopharma Inc reported Revenue decrease in the 3 quarter 2023 year on year by -96.68 %, despite the revenue increase by the most of its competitors of 3.16 %, recorded in the same quarter.

• List of AMAM Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Ambrx Biopharma Inc , faster than the decline experienced by the competitors recorded a net loss, as well as most of its competitors.

<< AMAM Stock Performance Comparisons

<< See the full list of AMAM competitors

Overall company Market Share Q3 2023

Overall company, revenue fell by -96.68 % and company lost market share, to approximately 0 %. << More on AMAM Market Share.

*Market share is calculated based on total revenue.

AMAM's Stock Performance relative to its Competitors

Publicly Traded Peers of Ambrx Biopharma Inc

Vir Biotechnology Inc
Share Performance

+77.02%

This Year

Vir Biotechnology Inc

Profile

Vir Biotechnology Inc is a clinical-stage immunology company that focuses on developing and commercializing innovative treatments for infectious diseases. Their business model revolves around the discovery and development of antibody therapies and other immunological approaches to combat a wide range of viral pathogens. They collaborate with leading research institutions and pharmaceutical companies to accelerate the development and commercialization of their products.

More about Vir Biotechnology Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 1,775.764 mill.	$ 303.227 mill.	$ -251.679 mill.

Checkpoint Therapeutics inc
Share Performance

+29.48%

This Year

Checkpoint Therapeutics inc

Profile

Checkpoint Therapeutics Inc is a biopharmaceutical company that develops and commercializes immune-targeted therapies for the treatment of cancer. The company mainly focuses on acquiring, developing, and commercializing targeted immunotherapy and immuno-oncology products. Through collaborations and strategic partnerships, Checkpoint Therapeutics aims to bring innovative and effective therapies to patients while creating value for shareholders.

More about Checkpoint Therapeutics inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 254.848 mill.	$ - mill.	$ -56.507 mill.

Calidi Biotherapeutics Inc
Share Performance

-24.23%

30 Days

Calidi Biotherapeutics Inc

Profile

Calidi Biotherapeutics Inc's business model revolves around developing and commercializing innovative cell-based immunotherapies for the treatment of cancer.

More about Calidi Biotherapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 1.749 mill.	$ - mill.	$ -17.508 mill.

Compass Therapeutics Inc
Share Performance

-42.44%

One Year

Compass Therapeutics Inc

Profile

Compass Therapeutics Inc operates as a biotechnology company focused on discovering and developing novel antibody therapeutics for the treatment of cancer and autoimmune diseases. Their business model revolves around leveraging their proprietary Targeted Immunomodulation platform to identify and advance multiple antibody candidates through preclinical and clinical development stages.

More about Compass Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 383.870 mill.	$ - mill.	$ -73.446 mill.

Cardiol Therapeutics inc
Share Performance

+86.11%

This Quarter

Cardiol Therapeutics inc

Profile

Cardiol Therapeutics Inc. operates on a business model focused on the research and development of pharmaceutical-grade cannabidiol (CBD) and targeted therapies for cardiovascular diseases. The company aims to leverage its expertise to develop innovative and effective treatments to address unmet medical needs in the field of heart-related conditions.

More about Cardiol Therapeutics inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 174.849 mill.	$ - mill.	$ -25.905 mill.

63 more competitors available

Sources: Ambrx Biopharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Saturday, September 12, 2026 6:39 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ambrx Biopharma Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.